Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 2063 for:    Pancreatic Cancer AND Digestive System Neoplasms

Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery (CLIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02446379
Recruitment Status : Withdrawn (Technology licensed to third party. Sponsor did not proceed with study.)
First Posted : May 18, 2015
Last Update Posted : January 26, 2017
Sponsor:
Collaborator:
Semmelweis University
Information provided by (Responsible Party):
Lightpoint Medical Limited

Brief Summary:

This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer.

EnLightTM will be used to detect positron emission and the LightPathTM system to detect Cerenkov Luminescence. Both are emitted by the Positron Emission Tomography (PET) agent.

The study will also evaluate the patient safety and radiation safety of the EnLightTM, and the safety for the device operators and surgical staff of the LightPathTM Imaging System.


Condition or disease Intervention/treatment
Gastric Cancer Pancreatic Cancer Bile Duct Cancer Duodenal Cancer Drug: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose Device: EnLightTM Device: LightPathTM Imaging System

Detailed Description:

This is a pilot study that is prospective, open-label, single-centre in nature in patients with gastric, pancreas, bile duct or duodenal cancer in whom tumour excision surgery is indicated.

Patients who give written informed consent will be screened for the study (Visit 1). Patients will undergo a positron emission tomography (PET) whole body scan. Screening assessments, including the PET scan, must be performed no less than 60 days before surgery and may be performed on the day of surgery.

On the day of surgery (Visit 2), subject's blood glucose level will be measured. Subjects with a blood glucose level < 12 mmol/l will receive an intravenous injection of 2-5 Mega Becquerel/kg (MBq/kg), up to a maximum 300 MBq of fluorine-18 fluorodeoxyglucose (18F-FDG) prior to surgery.

During surgery and not less than 120 minutes after injection of FDG, the primary lesion will be imaged using the EnLightTM system to determine margin status.

Gastrointestinal tumour excision surgery will then be performed according to standard of care. The surgical cavity and the lymph nodes will be imaged by the EnLightTM system to establish whether other radioactive tissue remain. These results will not influence any surgical or clinical decision-making, which will remain as standard of care. The resected tumour excision specimen will be imaged by the LightPathTM Imaging System. The resected tumour excision specimen will, in addition, be analysed according to standard of care pathology. The surgeon and surgical staff will be monitored for external exposure to ionizing radiation by means of dosimeters, and position sensors during surgery.

Patients will be followed-up (Visit 3) within a 2 - 14 day window after the end of surgery for adverse events (AEs). Those related to the use of the investigational devices, or the PET imaging agent will be identified as such.


Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery
Actual Primary Completion Date : January 1, 2016


Group/Cohort Intervention/treatment
EnLightTM and LightPathTM Imaging Systems arm

Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.

The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs).

Drug: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose
The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
Other Name: FDG

Device: EnLightTM
The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.

Device: LightPathTM Imaging System
The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.




Primary Outcome Measures :
  1. The location of PET imaging agent as measured by beta particle detection [ Time Frame: Intraoperatively (during the single session of surgery on Day 0) ]
    The EnLightTM will be used for determining the number of lesions, their location and margin status, in the surgical cavity including within surrounding tissue, and lymph nodes. The EnLightTM is a beta particle detector used for imaging the location of the PET imaging agent. It works both in a hot-spot mode, to localise areas with high beta particle detection signal from the PET imaging agent, and in an imaging mode that allows video imaging of areas where the PET imaging agent has accumulated.

  2. The location of PET imaging agent as measured by the LightPathTM Imaging System [ Time Frame: Intraoperatively (during the single session of surgery on Day 0) ]
    The LightPathTM Imaging System will be used for determining the margin status of lesions and the metastatic involvement of lymph nodes.


Secondary Outcome Measures :
  1. The number of lesions by histopathology [ Time Frame: Expected on average Day 10 after surgery ]
    Number of lesions according to standard of care histopathology.

  2. The number of metastatic lymph nodes by histopathology [ Time Frame: Expected on average Day 10 after surgery ]
    The number of metastatic lymph nodes according to standard of care histopathology.

  3. The extent of resection margins by histopathology [ Time Frame: Expected on average Day 10 after surgery ]
    Extent of resection margins according to standard of care histopathology.

  4. Ease of use measured by questionnaire [ Time Frame: At the end of imaging on Day 0 ]
    Ease of use measured by study-specific questionnaire

  5. Radiation exposure [ Time Frame: At the time of discharge to the ward after surgery on Day 0 ]
    Radiological dose in microsieverts as measured by dosimeters worn by operating room staff

  6. Number of participants with adverse events [ Time Frame: Visit 3, at day 3-15 ]
    Patients will be followed-up until Visit 3, 2-14 days after the end of surgery on Day 0 for adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Female or male patients aged ≥ 30 years diagnosed with gastric, pancreatic, bile duct or duodenal cancer, whose treatment is to be tumour excision surgery.
Criteria

Inclusion Criteria:

  1. Provides written informed consent to participate in the study.
  2. Is a man or woman aged ≥ 30 years.
  3. Patients diagnosed with gastric, pancreatic, bile duct or duodenal cancer whose treatment is to be tumour excision surgery.
  4. Life expectancy of at least 12 months.
  5. Blood glucose level < 12 mmol/l.

Exclusion Criteria:

  1. Participation in another clinical study either concurrently or within 180 days prior to surgery.
  2. Major surgery within 30 days before the baseline visit.
  3. Women who are pregnant or lactating.
  4. Renal impairment, hepatic impairment, serious infection or other life-threatening illness, other than cancer, within 60 days before surgery.
  5. Previous exposure to ionizing radiation >5 millisieverts (mSv) in the previous 12 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02446379


Locations
Layout table for location information
Hungary
Semmelweis University First Clinic of Surgery
Budapest, Hungary
Sponsors and Collaborators
Lightpoint Medical Limited
Semmelweis University
Investigators
Layout table for investigator information
Study Director: Sheryl O'Farrell, PhD Head of Clinical Development

Additional Information:
Layout table for additonal information
Responsible Party: Lightpoint Medical Limited
ClinicalTrials.gov Identifier: NCT02446379     History of Changes
Other Study ID Numbers: LPM-005
First Posted: May 18, 2015    Key Record Dates
Last Update Posted: January 26, 2017
Last Verified: January 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Bile Duct Neoplasms
Digestive System Neoplasms
Gastrointestinal Neoplasms
Duodenal Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Biliary Tract Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Intestinal Neoplasms
Cholangiocarcinoma
Gastrointestinal Diseases
Bile Duct Diseases
Biliary Tract Diseases
Adenocarcinoma
Carcinoma
Duodenal Diseases
Intestinal Diseases
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action